Patents by Inventor Paolo RONCHI

Paolo RONCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240116947
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Paolo RONCHI, Matteo BIAGETTI, Sara GUARIENTO, Claudio FIORELLI
  • PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240116948
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20240025880
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 25, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
  • PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
    Publication number: 20240018122
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 18, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20230092892
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: March 23, 2023
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Charles BAKER-GLENN, Hervè VAN DE POËL, Kim Louise HIRST
  • AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
    Publication number: 20220227749
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: May 28, 2020
    Publication date: July 21, 2022
    Inventors: Paolo BRUNO, Matteo BIAGETTI, Claudio FIORELLI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Charles BAKER-GLENN, Hervè VAN DE POËL, Kim Louise HIRST, Sara GUARIENTO
  • ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20220175784
    Abstract: The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them and therapeutic use thereof in the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Matteo BIAGETTI, Paolo RONCHI, Claudio FIORELLI, Paolo BRUNO